Business Wire

IQM's Q-Exa Consortium Selected to Integrate German Quantum Computer Into HPC Supercomputer for the First Time

Share

IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. The delivery is part of a €45.3 million consortium project. The project is funded by the German Federal Ministry of Education and Research (BMBF) with €40.1 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115006110/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Picture: Federal Minister Anja Karliczek hands over the grant certificate to Jan Goetz, CEO of IQM Picture credit: BMBF/Hans-Joachim Rickel

The highly interdisciplinary consortium with experts from quantum physics and computer science, from research centers and industry, will integrate a quantum computing system provided by IQM into an HPC environment via a research purchase. This will be the first time that a gate-based quantum system will be coupled with an HPC system, making quantum acceleration of HPC applications a reality.

Quantum computers have significant potential for solving a certain class of scientific and industrial problems that cannot be addressed by classical supercomputers. To meet this challenge, HPC centers around the world are looking for ways to integrate quantum accelerators into their computing infrastructure. The ability to provide on-site solutions for quantum computing in conjunction with supercomputers is essential for the development of cutting-edge high-tech solutions from Europe. The main goal of the Q-Exa project is to establish such solutions and thus strengthen the application- related use of quantum technologies from Germany.

IQM will work with Leibniz Supercomputing Centre, LRZ - one of Germany's three national supercomputing centers, Europe's leading HPC and quantum system provider (Atos) and one of Germany's leading innovators of quantum computing applications (HQS) on this project.

Q-Exa's collaborative approach creates strong synergies with other research projects in the German and European ecosystem. The previously announced BMBF project DAQC benefits from novel simulators and fits seamlessly into the concept of the Q-Exa Co-Design Lab. The new Co-Design lab will accelerate the path to self-sustaining quantum computing, the so-called quantum advantage, through industry partnerships. This approach is in line with other German industry efforts, such as the recently formed QUTAC consortium. On the application side, research consortia such as the BMBF projects QLindA, MANIQU and other initiatives support development as industrial use cases can be tested on the Q-Exa demonstrators. Finally, the Q-Exa project supports the European strategy based on integrating quantum computing accelerators into European HPC centers. With Q-Exa, Germany can make an active contribution to these European efforts.

Federal Research Minister Anja Karliczek says: "The international race in the field of quantum technologies is in full swing. Germany and the European Union must do their utmost to keep pace in order to guarantee our technological sovereignty. We want to be able to autonomously use the technology and develop it further. The Q-Exa project opens a new promising chapter on our path to a quantum computer 'made in Germany'. Integrating a quantum computer with the infrastructure of the Leibniz Supercomputing Centre harbours enormous potential for science and industry. The project will contribute to bringing quantum computers close to practice and to provide specific application scenarios for users in science and industry. I am delighted that by launching the project we have reached the first milestone on the way towards a competitive quantum computer 'made in Germany'."

Dr. Jan Goetz, CEO of IQM Quantum Computers remarks: "We are pleased to deliver a quantum computing system to LRZ and to work with the consortium partners to integrate this system into a production-grade HPC environment. I am grateful to the Federal Ministry of Education and Research in Germany, which has given us the necessary trust and support for this ambitious project. Together we will work hard to make European technology competitive and develop the most promising hardware solutions for quantum computing here in Germany".

Prof. Dr. Dieter Kranzlmuller, Chairman of the Board of Directors, LRZ, points out: “The Q-Exa project is key for our activities within the LRZ Quantum Integration Centre (QIC) and the Munich Quantum Valley (MQV). Working with this extremely competitive consortium, we will be able to set European standards that are competitive on a global scale. Ultimately, this will be for the benefit of society as the integration of quantum computing into supercomputers, in particular on the exascale level, will speed up and open vast new research possibilities. It will bring quantum computing to users – both in academia and in industry. And now is exactly the right time to realize this in a data center environment”.

“Technological sovereignty in strategic areas like quantum computing is critical for Europe. With our Quantum Learning Machine (QLM) and strong startup partners like IQM, Atos is proud to contribute to this joint effort. It is time to build the first German quantum computer, connected to an HPC datacenter through our QLM”, says Udo Littke, Head of Atos Central Europe.

„Quantum computers will accelerate scientific progress and the development of new technologies in many areas. Chemistry, physics and biology can potentially profit from the ability to perform improved quantum mechanical simulations. Therefore, it is the next logical step to integrate quantum computers into high performance computer centers like the LRZ. We are looking very much forward to connect the end users of the LRZ with the necessary software tools to make full use of the coming computational capabilities”, says Dr. Michael Marthaler, CEO HQS Quantum Simulations GmbH.

About IQM Quantum Computers:

IQM is the Pan-European category leader in building quantum computers.

IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to develop application-specific quantum processors by the German Ministry of Education and Research in February 2021.

IQM has raised €71 million from private and public funding and has offices in Munich, Germany; Espoo, Finland; and Bilbao, Spain.

For more information, visit www.meetiqm.com.

IQM: Facts and Figures

  • Number of employees currently (November 2021): 130+ employees
  • Funding: Over € 71 Million from private and public funding
  • Founding Year: 2018

Founders:

  • Dr. Jan Goetz, CEO, Co-founder of IQM
  • Dr. Kuan Yen Tan, CTO, Co-founder of IQM
  • Prof. Mikko Mottonen, Chief scientist, Co-founder of IQM
  • Dr. Juha Vartiainen, COO, Co-founder of IQM

For more information, visit www.meetiqm.com.

Registered offices:

IQM Finland Oy Keilaranta 19
02150 Espoo Finland

IQM Germany GmbH Nymphenburgerstr. 86 80636 Munchen Germany

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Raghunath Koduvayur, Head of Marketing and Communications
Raghunath@meetiqm.com, +358504876509

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye